Skip to main content

Peripheral Vascular Diseases

6
Pipeline Programs
14
Companies
12
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
2 programs
1
ABSOLUTE™: Self-Expandable Peripheral Nitinol StentPhase 41 trial
Treatment with CSI atherectomy deviceN/A1 trial
Active Trials
NCT03455374Terminated10Est. May 2019
NCT00180505Completed120Est. Oct 2009
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
Propionyl-L-CarnitinePhase 31 trial
Active Trials
NCT00399919Completed69Est. Mar 2008
Bayer
BayerLEVERKUSEN, Germany
1 program
1
VasovistPhase 31 trial
Active Trials
NCT00296855Completed261Est. Feb 2007
Design Pharmaceuticals
1 program
1
Autologous Bone Marrow Mononuclear CellsPhase 1/2
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
MK-0736Phase 1
MSD
MSDIreland - Ballydine
1 program
1
MK-0736Phase 11 trial
Active Trials
NCT00679055Terminated14Est. Aug 2008
Boston Scientific
Boston ScientificCA - Valencia
1 program
Any eligible commercially available Boston Scientific CorporationN/A1 trial
Active Trials
NCT04674969Recruiting5,000Est. Jan 2028
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Multispectral Optoacoustic TomographyN/A1 trial
Active Trials
NCT05110677Unknown9Est. Jul 2022
Medtronic
MedtronicNJ - Phillipsburg
1 program
PROTÉGÉ® EverFlex™ Self-Expanding Stent SystemN/A1 trial
Active Trials
NCT00530712Completed287Est. Jul 2013
Bristol Myers Squibb
1 program
Screening DIVA - Diffuse Vascular DiseaseN/A1 trial
Active Trials
NCT01076738Completed2,233Est. Jun 2010
Sanofi
SanofiPARIS, France
1 program
Screening DIVA - Diffuse Vascular DiseaseN/A
Design Therapeutics
1 program
Autologous Bone Marrow Mononuclear CellsPHASE_1_21 trial
Active Trials
NCT00872326Completed20Est. May 2009
Cordis
CordisFL - Miami Lakes
1 program
Sirolimus-Eluting BX Velocity Balloon-Expandable StentPHASE_1_21 trial
Active Trials
NCT00489164Terminated83Est. May 2004
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
SM-01PHASE_31 trial
Active Trials
NCT01183117Completed105Est. Aug 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AbbottABSOLUTE™: Self-Expandable Peripheral Nitinol Stent
Johnson & JohnsonSM-01
Colorado TherapeuticsPropionyl-L-Carnitine
BayerVasovist
Design TherapeuticsAutologous Bone Marrow Mononuclear Cells
CordisSirolimus-Eluting BX Velocity Balloon-Expandable Stent
MSDMK-0736
Heidelberg PharmaMultispectral Optoacoustic Tomography
Boston ScientificAny eligible commercially available Boston Scientific Corporation
AbbottTreatment with CSI atherectomy device
Bristol Myers SquibbScreening DIVA - Diffuse Vascular Disease
MedtronicPROTÉGÉ® EverFlex™ Self-Expanding Stent System

Clinical Trials (12)

Total enrollment: 8,211 patients across 12 trials

NCT00180505AbbottABSOLUTE™: Self-Expandable Peripheral Nitinol Stent

ASSESS Study: Evaluation of ABSOLUTE™ Stent System for Occluded Arteries

Start: Mar 2005Est. completion: Oct 2009120 patients
Phase 4Completed
NCT01183117Johnson & JohnsonSM-01

A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease

Start: Jul 2010Est. completion: Aug 2014105 patients
Phase 3Completed
NCT00399919Colorado TherapeuticsPropionyl-L-Carnitine

Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)

Start: Apr 2006Est. completion: Mar 200869 patients
Phase 3Completed
NCT00296855BayerVasovist

Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease

Start: Feb 2006Est. completion: Feb 2007261 patients
Phase 3Completed
NCT00872326Design TherapeuticsAutologous Bone Marrow Mononuclear Cells

Autologous Bone Marrow Derived Mononuclear Cells in Treating Diabetic Patients With Critical Limb Ischemia

Start: Dec 2007Est. completion: May 200920 patients
Phase 1/2Completed
NCT00489164CordisSirolimus-Eluting BX Velocity Balloon-Expandable Stent

Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions

Start: Aug 2002Est. completion: May 200483 patients
Phase 1/2Terminated
NCT00679055MSDMK-0736

A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)

Start: Mar 2007Est. completion: Aug 200814 patients
Phase 1Terminated
NCT05110677Heidelberg PharmaMultispectral Optoacoustic Tomography

Pilot Study of Topographic Imaging of the Calf Muscle in Patients With PAD Using 3D Reconstruction of MSOT Images

Start: Nov 2021Est. completion: Jul 20229 patients
N/AUnknown
NCT04674969Boston ScientificAny eligible commercially available Boston Scientific Corporation

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Start: Mar 2021Est. completion: Jan 20285,000 patients
N/ARecruiting
NCT03455374AbbottTreatment with CSI atherectomy device

Diamondback in Peripheral Vascular Disease

Start: Aug 2017Est. completion: May 201910 patients
N/ATerminated
NCT01076738Bristol Myers SquibbScreening DIVA - Diffuse Vascular Disease

Screening DIVA - Diffuse Vascular Disease

Start: Apr 2009Est. completion: Jun 20102,233 patients
N/ACompleted
NCT00530712MedtronicPROTÉGÉ® EverFlex™ Self-Expanding Stent System

Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis

Start: Aug 2007Est. completion: Jul 2013287 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 8,211 patients
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.